Inactive Instrument

Highlights Epizyme, Inc.

Equities

EPZM

US29428V1044

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme	22-08-14	MT
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Management LLC and others.	22-08-10	CI
Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M	22-08-09	MT
Epizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme	22-08-05	MT
Epizyme Agrees to be Acquired by Ipsen for $247 Million	22-06-27	MT
France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme	22-06-27	MT
Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. from RP Management LLC and others for approximately $250 million.	22-06-26	CI
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting	22-06-02	CI
HUTCHMED Secures Regulatory Clearance for Use of Oncology Drug Tazverik in China's Hainan Medical Tourism Pilot Zone	22-06-01	MT
Earnings Flash (EPZM) EPIZYME Posts Q1 Revenue $8.7M	22-05-10	MT
Epizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Epizyme, Inc. Provides Tazemetostat Clinical Update	22-03-15	CI
Epizyme, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-03-01	CI
Epizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Epizyme to Seek Acquisitions	22-01-28	CI
Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021	22-01-10	CI
Epizyme, Inc. Receives Written Notice from Glaxo Group Limited to Terminate the Collaboration and License Agreement	21-12-22	CI
Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting	21-12-12	CI
Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting	21-12-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Epizyme, Inc.

Equities

EPZM

US29428V1044

Highlights

Filters